【背景知识】 不对称二甲基-L-精氨酸是NO合酶的内源性抑制剂。它是在甲基化蛋白质分解过程中形成的,通过肾脏消除或通过二甲基精氨酸二甲基氨基水解酶代谢。各种细胞类型,包括人类内皮细胞和肾小管细胞,合成和代谢不对称二甲基精氨酸。不对称二甲基精氨酸的血液水平在许多与内皮功能障碍相关的疾病中升高。例如,在透析患者中,升高的不对称二甲基精氨酸血液水平与动脉粥样硬化的严重程度和心血管风险显着相关。在患有高胆固醇血症、高血压、动脉硬化、慢性肾功能不全和慢性心功能不全的患者中检测到不对称二甲基精氨酸浓度升高,并与受限的内皮依赖性血管舒张有关。 近年来,NO对血管张力和结构的调节具有重要的临床意义。也有报道称,人内皮细胞除NO外还产生不对称二甲基精氨酸,这表明内源性NO的调节是通过内皮中的不对称二甲基精氨酸因此推测肾功能不全患者高血压、动脉硬化和免疫功能障碍的多发与L-精氨酸/NO代谢受损和不对称二甲基精氨酸的蓄积密切相关。迄今为止,导致 L-精氨酸-NO 代谢变化的机制仅部分阐明。当然,这是一个多因素的现象,i.a.自由基增加,不对称二甲基精氨酸积累和 NO 合酶活性降低。
适应症:
动脉硬化
高血压
心脏衰竭
冠状动脉心脏疾病
高胆固醇血症
肾功能不全
糖尿病
外周动脉疾病
参考文献: 1. BogerRH, Bode-Boger SM, Szuba A, Tangphao O, Tsao PS,Chan JR, Blaschke TF,Cooke JP.Asymmetric dimethylarginine: a novel risk factor for endothelialdysfunction. lts role in hypercholesterolemia.Circulation 1998;98: 1842-18472. 2. Boger RH. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor.Cardiovasc. Res. 2003;59:824-833 3. Kielstein JT, Boger RH,Bode-Boger SM, et al.Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease:Relationship to treatment method and atherosclerotic disease. J. Am. Soc.Nephrol. 1999; 10:594-600 4. Lu TM,Ding YA,Lin SJ,Lee WS,Tai HC. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneouscoronary intervention.Eur Heart J.2003;24: 1912-1919 5. Nijveldt RJ,Teerlink T, Van der Hoven B, Siroen MP, Kuik DJ, Rauwerda JA, van Leeuwen PA. Asymmetrical dimethylarginine in critically ill patients:high plasma Asymmetric dimethylarginine concentration is an independent risk factor of lCU mortality.Clin. Nutr. 2003;22:23-30 6. Savvidou MD,Hingorani AD,Tsikas D, Frolich JC, Vallance P,Nicolaides KH.Endothelial dysfunction and raised plasma concentrations of asymmetricdimethylarginine in pregnant women who subsequently develop pre-eclampsia.Lancet 2003;361: 1511-1517 7. Stühlinger M, AbbasiF, Chu JW, Lamendola C, McLaughlin TL, Cooke JP,Reaven GM,Tsao PS.Relationship between insulin resistance and an endogenous nitricoxide synthase inhibitor.J.Am. Med.Assoc. 2002;287:1420-1426 8. Vallance P,Leone A, Calver A, Collier J,Moncada S. Accumulation of an endogenous inhibitor of NO synthesis in chronic renal failure.Lancet 1992;339:572-575 9.Zoccali C,Bode-Boger SM,Mallamaci F, Benedetto FA,Tripepi G, Malatino L,Cataliotti A,Bellanuova l, Fermo l, Frolich JC, Boger RH. Asymmetric dimethylarginine: An endogenous inhibitor of nitric oxide synthasepredicts mortality in end-stage renal disease (ESRD).Lancet 2001; 358:2113-2117 10.Dzikowska-Diduch O, Kostrubiec M, Domienik-Karlowicz J, Wyzgal A, Labyk A,Radochonska J, Gorska E, Demkow u, Pruszczyk P.Endothelial Dysfunction inPatients with History of Pulmonary Embolism.Eur Heart J.2010,34 (suppl 1):202-203 11.Watarai R, Suzuki K, Ichino N, Osakabe K, Sugimoto K, Yamada H, Hamajima T,Hamajima N, Inoue T.Association between serum levels of carotenoids andserum asymmetric dimethylarginine levels in japanese subjects.Epidemiol2014,24(3):250-257